MVT-2163

Optimizing PET Scan Imaging

MVT-2163 is a positron emission tomography (PET) imaging agent. We initiated the MVT-2163 PET imaging trial in July of 2016 at Memorial Sloan Kettering. This product is based on the MVT-5873 antibody with the radiolabel Zirconium 89 attached to the antibody. This PET agent can potentially be an important tool to aid in the diagnosis, monitoring and assessment of pancreatic cancer patients and an attractive companion diagnostic for the MVT-5873 therapeutic product.

Program Collaborators Discovery Pre-IND Phase 1
MVT-2163 PET Imaging Metastatic Pancreatic & GI Cancers NIH, MSKCC, SCRI, Patheon
Discovery Phase complete
Pre-IND Phase complete
Phase 1 Phase in progress
Commercial Rights: WW

Clinical Trials

The Phase I clinical trial for MVT-2163 will determine the ideal dose and conditions for an optimal PET scan imaging. The trial was initiated in July of 2016 in subjects with stage 3 and 4 metastatic pancreatic cancer. The objectives of the trial include:

  • Determination of safety as a single agent and in combination with MVT-5873 as a blocking dose
  • Determination of the recommended dose of MVT-5873 required for optimal tumor visualization
  • Determination of the optimal time interval between dose administration and tumor PET imaging
  • Determination of the pharmacokinetics and distribution of MVT-2163
  • Evaluation of the ability of MVT-2163 to detect sites of disease (localized and metastatic)

Clinical Trials Results

  • The company has completed the first three dosing cohorts outlined in the clinical protocol and has expanded the third cohort based on positive data and will complete this portion of the study in the first half of 2017.
  • The results from these first cohorts of subjects indicate that the administration of increasing levels of a blocking dose of MVT-5873 improve image quality. Preliminary data indicate that expanding the time lag between the administration of the blocking dose and the MVT-2163 radiolabeled product also improves image quality.
  • The MVT-2163 PET images have established antibody specificity for the cancer and no observed binding to other normal tissues.
  • MVT-2163 PET images correlate very well with diagnostic CT scans..
  • Given the positive results to date from this study, the MVT-2163 product could play an important role in determining whether patients would be eligible for potentially curative surgery. Improved imaging capabilities would play a critical role in this decision allowing some patients to have an improved opportunity for successful surgery or avoid a potentially unsuccessful and debilitating surgery.